Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Summary

To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.

Timeline

Start

2016-11

Primary completion

2018-02-17

Completion

2018-02-17

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient recruitment rate”

Drugs

Indications